The role of epigenetic mechanisms in the regulation of the human RORgT gene, which encodes a Th17 lymphocyte signature transcription factor, remains largely unknown. We investigated the effect of histone deacetylase (HDAC) inhibition on RORgT and RORgT-dependent gene expression in human T lymphocytes. We found that, in Jurkat T cells and in in vitro-differentiated Th17 cells, treatment with 2 HDAC inhibitors, butyrate and apicidin, led to the induction of the RORgT gene, which was associated with an increase in histone H4 acetylation near the RORgT proximal promoter. In contrast, when the same inhibitors were added to naive CD4 + cells differentiating in vitro to Th17 cells, they mediated the down-regulation of RORgT expression. In conclusion, HDAC inhibitor-mediated H4 acetylation is involved in the epigenetic regulation of RORgT expression in Th17 cells. However, that epigenetic mechanism was observed only at a specific stage of T cell differentiation, suggesting a complex interaction with additional mechanisms that sequentially regulate RORgT expression. These observations may be relevant to the development of applications for HDAC inhibitors for diseases in which Th17 cells have a role in pathogenic mechanisms, such as some types of cancer or autoimmunologic disorders, to prevent unwanted side effects.
Introduction
RORgT and RORg, 2 isoforms of a nuclear receptor in the NR1 subfamily, are derived from the use of alternate promoters within the same RORC gene [1] [2] [3] . The 2 proteins differ in their N-terminal domains by 21 aa. The longer RORg version is more broadly expressed and seems to be involved in the regulation of the circadian cycle and metabolism [4] [5] [6] . Expression of the shorter isoform RORgT is limited to the Th17 subset of T lymphocytes that secrete IL-17A and 17F. RORgT orchestrates the differentiation of Th17 cells from naive CD4 + cells and is considered a signature TF for this subset of T cells [7] , similar to the TFs t-bet (Th1) [8] , GATA3 (Th2) [9] , and FOXP3 (T reg ) [10] . In recent years, Th17 cells have been identified as pathogenic cells that induce tissue damage in numerous autoimmune diseases, including multiple sclerosis [11] , rheumatoid arthritis [12] , psoriasis [13] , Grave's disease [14] , and inflammatory bowel disease [15] . Conversely, Th17 cells are important in host defense mechanisms, particularly in the clearance of infections caused by Bacillus anthracis [16] , Staphylococcus aureus [17] , and Candida albicans [18] [19] [20] .
Most knowledge regarding the mechanisms regulating the expression of RORgT has come from mouse model studies, which have revealed the involvement of several TFs acting as positive or negative regulators of the gene, e.g., STAT3, IRF4, c-Rel, Id1, E2A, HEB, Sox5, c-Maf, TCF1, and ER [21] [22] [23] [24] [25] [26] [27] [28] [29] , as well as epigenetic pathways linked to HDACs [29] , [30] . The 59 proximal region of human RORgT contains 4 conserved E-boxes capable of binding USF TFs [3] and 2 primate-specific GC-boxes that are indispensable for promoter activity and are occupied by the TFs Sp1 and Sp2 [31, 32] . Relatively little is known about the epigenetic pathways involved in the regulation of human RORC. However, Schmidl et al. [33] have shown that the RORC locus is methylated in cells with low expression of RORC, and there is increasing evidence that the gene is also regulated by histone acetylation [29, 34] .
Genetic expression depends on the outcome of the activities of all regulatory pathways acting in the cell at a given time, at both the transcriptional and epigenetic levels. We decided to investigate the role of regulatory pathways involving histone 1 
MATERIALS AND METHODS

Cell culture and reagents
The Jurkat (human T cell lymphoblast-like) cell line was purchased from ATCC (Manassas, VA, USA) and was maintained under standard conditions in RPMI-1640 containing 10% FBS (PAN-Biotech GmbH, Aidenbach, Germany) at 37°C in an atmosphere of 5% CO 2 . Sodium butyrate and apicidin were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Naive CD4 + T cell isolation and differentiation
Human Th17 cells were generated according to the protocol described previously by Wilson et al. [35] . PBMCs were isolated from buffy coats obtained from healthy, anonymous donors by Ficoll gradient centrifugation. The naive CD4 + fraction was isolated with CD4 M-pluriBead anti-hu (pluriSelect Life Science, Leipzig, Germany) and then maintained in Yssel's medium containing human AB serum with beads coated with anti-CD2, anti-CD3, and anti-CD28 [T cell activation/expansion kit from Miltenyi Biotec (Bergisch Gladbach, Germany)] for 5 d under Th17-polarizing conditions with a cytokine cocktail of human IL-1b (50 ng/ml), human IL-6 (30 ng/ml), human IL-23 (10 ng/ml), and human TGF-b (10 ng/ml). The cytokines were purchased from R&D Systems (Minneapolis, MN, USA).
Plasmids and transfection
The promoter constructs for the RORgT gene were described in our previous studies [3, 31] . Jurkat T cells were transfected with FuGENE HD (Promega, Madison, WI, USA). The reporter plasmid (RORE) 6 -tk-Luc was generated by inserting 6 copies of chemically synthesized RORE (59-GGTAAGTAGGTCA-39) [36] and the tk promoter into the Acc65I/HindIII sites of the pGL4.14 vector (Promega, Madison, WI, USA). The luciferase activity in the cell lysates was measured in 96-well, white plates on an Infinite 200 PRO reader (Tecan, Männedorf, Switzerland). Alkaline phosphatase activity was determined spectrophotometrically at 405 nm in culture medium and was used as a transfection efficiency control (the vector pCMV-SEAP was a kind gift from Dr. S. Schlatter, Eidgenoessische Technische Hochschule, Zurich, Switzerland). Luciferase activities were normalized to the corresponding SEAP activity. 
Real-time RT-PCR
was determined by real-time RT-PCR and normalized to that of the housekeeping genes HPRT1, HMBS, and RPL13A. The data are presented as statistical dot plots with the median value (bars) from 8 independent experiments performed using cultures originating from 8 different donors (n = 8). IL-17 production (F) was analyzed using a Quantikine human IL-17 immunoassay kit (R&D Systems). An asterisk indicates a statistically significant difference at P , 0.05 compared with control cells. Statistical analysis was performed using the Friedman repeated-measures ANOVA on ranks followed by Tukey's post hoc test.
(continued from previous page) RORgT = RAR-related orphan receptor C transcript variant 2, RPL13A = ribosomal protein L13a, SEAP = secreted embryonic alkaline phosphatase, TF = transcription factor, tk = thymidine kinase previously [3] ; IL-17F, 59-CTTTCTGAGTGAGGCGGC-39 (forward) and 59-TGGGAACGGAATTCATGG-39 (reverse), described previously [31] ; IL-9, 59-TCCCTCTGACAACTGCACC-39 (forward) and 59-GTGGTTTGG-TTGCATGGC-39 (reverse); IL-21, 59-TCCCAAGGTCAAGATCGC-39 (forward) and 59-CCCTGCATTTGTGGAAGG-39 (reverse); IL-6, 59-CCTGAACCTTCCA-AAGATGG-39 (forward) and 59-GGTCAGGGGTGGTTATTGC-39 (reverse); and IL-6R, 59-GTTGTTTGTGAGTGGGGTCC-39 (forward) and 59-GTTTTGCTG-AACTTGCTCCC-39 (reverse).
Chromatin immunoprecipitation assay
The chromatin immunoprecipitation assay was performed using an EpiXplore ChIP Assay Kit (Clontech Laboratories, Mountain View, CA, USA). The following Abs were used: normal mouse IgG (MilliporeSigma, Billerica, MA, USA), antihistone H3ac (pan-acetyl) Ab (61637; Active Motif, Carlsbad, CA, USA), anti-acetyl histone H4 Ab (06-866; MilliporeSigma), antihistone H4 (acetyl K5) Ab (ab51997; Abcam, Milton, Cambridge, United Kingdom), antihistone H4 (acetyl K8) Ab (ab15823; Abcam), antihistone H4 (acetyl K12) Ab (ab46983; Abcam), and antihistone H4 (acetyl K16) Ab (61529; Active Motif). To detect the immunoprecipitated RORgT promoter region, quantitative PCR was performed with the primers 59-GTGCAGAGCTTAAAC-CCCC-39 (forward; position 2180) and 59-ACATCCTCCTTTCCAGAGGG-39 (reverse; position + 78), described previously [31] , for 40 cycles. Soluble chromatin collected before immunoprecipitation was amplified as an input control. The relative PCR product enrichment was calculated using the DCt method, with the Ct obtained for input DNA as a reference value as follows: 1000 3 2 2DCt , where DCt = Ct sample 2 Ct input DNA.
Analysis of IL-17 production
Cell culture supernatants were analyzed by ELISA using a Quantikine Human IL-17 Immunoassay kit (R&D Systems), according to the manufacturer's protocol. Microtiter plates were read in a Sunrise microplate reader (Tecan) at 405 nm.
Cell viability
Viability of differentiating and fully differentiated Th17 cells cultured in the presence of selected HDAC inhibitors for 5 d was determined using CellTiterGlo Luminescent Cell Viability Assay from Promega.
Statistics
Statistical analysis was performed using 1-way ANOVA followed by Tukey's post hoc test. The results obtained from human donors were analyzed using the Friedman repeated measures ANOVA on ranks, followed by Tukey's post hoc test. A P value of 0.05 or lower was considered statistically significant. Statistical analysis was performed using SigmaStat software (version 3.5; Systat Software, San Jose, CA, USA).
RESULTS
Effect of HDAC inhibitors on Th17 lymphocyte differentiation
To assess whether HDAC inhibitors can up-regulate RORgT expression and affect Th17 differentiation, we cultured naive CD4 + cells under Th17-polarizing conditions in the presence of butyrate and apicidin for 5 d. No concentrations of HDAC inhibitors used in this study exerted cytotoxic effects on the cells ( Supplementary Fig. 1 ). As shown in Fig. 1A , HDAC inhibitor treatment caused a significant decrease in RORgT mRNA expression, which was accompanied by inhibition of the expression (Fig. 1B and C) and secretion (Fig. 1F ) of IL-17A and IL-17F. This was associated with a decrease in the expression of several other genes known to be up-regulated upon Th17 lymphocyte differentiation [38, 39] (Fig. 1D and E) . When analyzing expression of IL-9, IL-21, and IL-6, we observed that both HDAC inhibitors caused significant decrease in their levels (Fig. 1D , E, and G). However, the nonidentical effects of apicidin and butyrate on the expression of IL-6R (Fig. 1H ) suggests different mechanisms of action for each compound. To better understand how HDAC inhibitors mediate RORgT inhibition, we analyzed the histone acetylation status at that gene locus. To that end, we examined the recruitment of ac-H3 and ac-H4 to the RORgT promoter in vivo using ChIP assays. As shown in Fig. 2A , although the amount of proximal promoter-bound ac-H3 was low and did not increase upon HDAC inhibitor stimulation, ac-H4 was detected at the RORgT promoter in resting cells, and its occupancy significantly increased upon treatment with sodium butyrate and apicidin. Thus, we unexpectedly found that HDAC inhibitor treatment caused an increase in histone H4 acetylation in the proximity of the RORgT promoter. Upon comparing the occupancy of acetylated H4 at the RORgT promoter in naive CD4 + cells and differentiated Th17 cells, we observed that the ac-H4 level was higher in Th17 cells (Fig. 2B) . The increase in the ac-H4 level associated with RORgT promoter was already observed at 24 h after the naive CD4 + was cultured under Th17-polarizing conditions (Fig. 2B) . This suggested that the HDAC inhibitor-mediated decrease in RORgT expression occurred in parallel with the increase in histone acetylation at that gene locus and that the level of histone acetylation in the RORgT promoter region increased during Th17 differentiation.
Regulation of RORgT-dependent and Th17-specific genes by HDAC inhibitors in differentiated Th17 lymphocytes
To determine whether the observed changes in the histone acetylation status of the RORgT locus affected gene expression in differentiated Th17 cells, human CD4 + cells were cultured under Th17-polarizing conditions for 5 d, and the Th17 cells obtained were then restimulated and treated with butyrate and apicidin for another 5 d. We observed a significant induction of RORgT mRNA in cells treated with both HDAC inhibitors (Fig. 3A) . The RORgT-dependent IL-17A and IL-17F also exhibited increased expression ( Fig. 3B and C) , which was accompanied by the upregulation of IL-17 secretion (Fig. 3F) . In contrast, the expression of IL-9 and IL-21 was not affected by HDAC inhibitor treatment ( Fig. 3D and E) . Similar to differentiating CD4 + cells, we also observed increased recruitment of acetylated histone H4 to the RORgT promoter (Fig. 4A ). An analysis of the pattern of acetylated lysine residues showed that both HDAC inhibitors caused an increase in ac-H4K16 but not in lysines-5, -8, and -12 (Fig. 4B) .
HDAC inhibitors up-regulate RORgT promoter activity and gene expression in Jurkat T cells
To gain additional insights into the molecular mechanism responsible for the observed effects of the HDAC inhibitors, we investigated the effects of sodium butyrate and apicidin on RORgT promoter activity in Jurkat T cells. We observed that both compounds were able to induce transcription from the RORgT promoter construct phRORgT(2869/ + 78)Luc in a concentration-dependent manner (Fig. 5A and B) . To determine which promoter elements mediated transcriptional activation by the HDAC inhibitors, we performed luciferase assays with a series of 59-deletion mutants. As shown in Fig. 5C , all promoter constructs were induced by HDAC inhibitor treatment; however, they exhibited different degrees of response. The shortest construct, phRORgT(2180/ + 78)Luc, which contained the basal promoter of the RORgT gene, was induced ;2-fold, whereas phRORgT(2341/ + 78)Luc and the other longer constructs were induced 3.4-and 4.4-fold, respectively. This suggests that all sequence elements responsible for the observed induction are located within the previously identified proximal promoter region of the gene [3, 31, 32] .
Next, we investigated the effects of the HDAC inhibitors on the endogenous RORgT gene in Jurkat cells. As shown in Fig. 6A , treatment with 1 mM butyrate caused a 3.4-and 2.7-fold induction of RORgT mRNA expression at 24 and 48 h, respectively. Treatment with apicidin led to a 2.2-and 3-fold increase in RORgT mRNA after 24 and 48 h, respectively. Because Jurkat cells do not express IL-17A and IL-17F, to investigate the potential effect of HDAC inhibitors on RORgTdependent transcription, we constructed a reporter vector containing RORE. Treatment with both compounds led to a significant induction of the reporter vector, and, in agreement (D), IL21 (E) was determined by real-time RT-PCR and normalized to that of the housekeeping genes HPRT1, HMBS, and RPL13A. The data are presented as statistical dot plots with the median value (bars) from 12 to 14 independent experiments performed using cultures originating from 12 to 14 different donors (n = 12-14). IL-17 production (F) was analyzed using a Quantikine human IL-17 immunoassay kit (R&D Systems). An asterisk indicates a statistically significant difference at P , 0.05 compared with control cells. Statistical analysis was performed using the Friedman repeated-measures ANOVA on ranks, followed by Tukey's post hoc test.
with the quantitative real-time PCR analysis of RORgT expression, the effects of butyrate and apicidin were strongest at 24 and 48 h, respectively (Fig. 6B) .
To determine whether sodium butyrate and apicidin enhance the recruitment of acetylated histones H3 and H4 to the RORgT promoter in vivo in Jurkat cells, ChIP assays were performed. Similar to undifferentiated CD4 + cells and to Th17 cells, the amount of ac-H3 bound to the proximal promoter was low and did not increase upon HDAC inhibitor treatment (Fig. 7A) , but the already observed high occupancy of ac-H4 at the RORgT promoter was significantly up-regulated with HDAC inhibitor treatment (Fig. 7A) . Next, we analyzed the acetylation status of 4 lysine residues in histone H4, following treatment with the HDAC inhibitors. Similar to Th17 cells, the acetylation of K16 increased (2.3-fold) after stimulation with apicidin, whereas the acetylation of K5 and K12 was unaffected. Unlike the results observed in Th17 cells, K8 acetylation was also increased by 1.8-fold after treatment with butyrate (Fig. 7B) .
DISCUSSION
The phenotype of a cell is a result of not only the information carried in its DNA sequence but also the information stored in the epigenetic marks that influence genetic expression without changing the DNA sequence [40] . The most common epigenetic mechanisms involved in gene regulation are modifications of DNA (methylation and hydroxymethylation) [41, 42] and posttranslational modifications of histones (acetylation, methylation, phosphorylation, ubiquitination, SUMOylation, and poly-ADPribosylation) [43, 44] .
RORgT is a crucial TF involved in the development of Th17 lymphocytes from naive CD4 + cells [7] , and although its regulation at the transcription level in mouse models and in humans is well understood [3, 21, 31, 32] , how the gene is regulated epigenetically remains elusive. There is increasing evidence that various HDACs are involved [29, 30] , although treatments with HDAC inhibitors have led to different, sometimes conflicting, results [29, [45] [46] [47] [48] . In this report, we investigated how HDAC inhibitors influence human RORgT expression in 3 cellular models: primary CD4 + cells differentiating toward Th17 cells, differentiated Th17 lymphocytes, and the Jurkat T cell line.
We showed that, when HDAC inhibitors were added to naive CD4 + cells cultured under Th17-polarizing conditions, a strong inhibitory effect on RORgT and RORgT-dependent gene transcription was observed (Fig. 1) , similar to the results of previous studies in mice [46, 49] , which showed that treatment of CD4 + cells with ITF2357 inhibits IL-6/IL-6R expression and, in turn, shifts the balance from Th17 cells to T regs . Interestingly, however, cells in which HDAC inhibitors inhibited RORgT expression still exhibited an increased amount of ac-H4 near the RORgT promoter (Fig. 2) . This observation suggests that HDAC inhibitor treatment leads to greater accessibility of the RORgT locus to transcription machinery without an increase in the actual transcription rate. This is similar to the results observed in trichostatin A-treated hippocampal cells, which exhibited a large change in acetylation at promoters that did not translate into up-regulation of the genes [50] . One potential explanation is involvement of other mechanisms critical for RORgT activation during Th17 differentiation, such as methylation or dissociation of repressor proteins, which counteract the positive regulatory signal mediated by histone acetylation. Alternatively, the indirect effect of HDAC inhibitors on the expression of other genes involved in a complex process of reprogramming genetic expression in differentiating CD4 + cells may override the stimulatory effect of these inhibitors on RORgT expression. Our results are in line with those published by Glauben et al. [46] , and Regna et al. [49] , suggesting the indirect effect of HDAC inhibitor on RORgT expression is mediated by a decrease in IL-6/IL-6R expression. On the other hand, our findings are somehow different than previously published observation by Chen et al. [29] showing that low doses (2.66 and 26.6 nM) of MS-275 induced, whereas high dose (266 nM) inhibited, RORgT expression. Taking into account the IC 50 values for all these inhibitors, our data with apicidin and butyrate applied at concentrations exceeding respective IC 50 are consistent with the Chen et al. [29] observation of an inhibitory effect of MS-275 at a concentration close to IC 50 [51] . A possible explanation for the observed differences between MS-275, apicidin, and butyrate could be different enzyme selectivity for these HDAC inhibitors [51] .
In contrast to differentiating CD4 + lymphocytes, the polyclonal population of differentiated Th17 cells and the monoclonal Jurkat T cell line responded to HDAC inhibitors by significantly increasing the expression of RORgT (Figs. 3 and 6A ). These observations are fully consistent with the strong stimulatory effect of HDAC inhibitors on activity of the proximal promoter in Jurkat T cells (Fig. 5) , which is known to be crucial for RORgT expression [31, 32] , as well as the observed activation of RORgTdependent transcription (Fig. 6B) . Thus, HDAC inhibitor-mediated The results are standardized to the corresponding SEAP activity, means 6 SD, n = 6. *Significantly different from the control treatment at P , 0.05. Statistical analysis was done using 1-way ANOVA followed by Tukey's post hoc test.
activation of the RORgT promoter leads to increased expression of a fully functional TF. In both cell systems, HDAC inhibitormediated RORgT expression was associated with an increase in the amount of lysine-16 ac-H4 (Figs. 4B and 7B) bound to the RORgT promoter region. This suggests that histone H4 acetylation is involved in the regulation of RORgT expression, possibly by directly interacting with the promoter region. This hypothesis is also supported by the observed increase in H4 acetylation at the RORgT locus upon the differentiation of naive CD4 + cells toward Th17 cells (Fig. 2B ). These observations are in agreement with previous studies showing that acetylated forms of histone H4 are preferentially associated with transcriptionally active regions and exhibit higher affinity for TF binding than acetylated forms of histone H3 [52] ; however, during differentiation of Th17 cells, the IL-17A/F locus at the regulatory CNS2 site becomes acetylated and trimethylated at Lys-4 (ac-H3 and H3K4me3) [53] , which allows binding of RORa and RORgT nuclear receptors to their response elements and induction of IL-17A/F expression [54] . However, when discussing the potential molecular mechanism of HDAC inhibitor-mediated effects on the expression of RORgT and RORgT-dependent genes, the effect of HDAC inhibitor on RORgT protein acetylation should also be considered [48] . The importance of HDAC activity in the regulation of the Rorgt gene was recently demonstrated using conditional knockout mice: Hdac3 was shown to be necessary for the inhibition of Rorgt gene expression during thymocyte-positive selection [30] . Using TNF-a inhibitors, as well as anacardic acid (an acetyltransferase inhibitor), Lin et al. [34] were able to down-regulate Rorgt expression in a process associated with a decrease in histone acetylation in its promoter. Additionally, Chen et al. [29] showed that Hdac1 and Hdac2 occupy the mouse Rorgt promoter at the ER element. Our results show that the effects of HDAC inhibition on human RORgT and RORgT-dependent gene transcription depend strictly on the stage of T cell differentiation. Such dual, time-dependent functions have already been described for valproic acid and Hdac1/2 knockdown in mouse preleukemic cells (tumor initiation) and in leukemic cells (tumor maintenance) [55] .
The observed effect of HDAC inhibitors on Th17 cells might be relevant to the further development of clinical applications for this class of therapeutic compounds, and it might be especially important in the treatment of diseases and processes with a significant Th17-dependent pathogenicity component. For example, 4 HDAC inhibitors (vorinostat, romidepsin, belinostat, panobinostat) are currently approved for the treatment of several types of cancer [56] . Although the role of Th17 lymphocytes in cancer is still controversial, it is well documented that Th17 cells are present in the tumor microenvironment [57] , and in some types of cancer, such as colon cancer [58] , hepatocellular carcinoma [59, 60] , colorectal cancer [61, 62] , pancreatic cancer [63] , and acute myeloid leukemia [64] , and their presence is correlated with poor prognosis. Thus, for the future expansion of HDAC inhibitor-based anticancer treatments, the information that some HDAC inhibitors are able to stimulate Th17 cells might be important.
In summary, we present evidence that the expression of the human RORgT gene is regulated by acetylation of K16 in histone H4 near the proximal promoter. HDAC inhibitors are able to increase H4K16 acetylation in that area. This HDAC inhibitor-mediated increase in the acetylation of H4K16 up-regulates RORgT expression in Th17 cells but not in undifferentiated CD4 + T lymphocytes. 
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